Biological Chemistry, Volume 392, Issue 10, Page 837-847, October 2011. more
To use all functions of this page, please activate cookies in your browser.
My watch list
my.chemeurope.com
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Recent progress and clinical importance on pharmacogenetics in cancer therapy
Abstract Recent advances have provided unprecedented opportunities to identify prognostic and predictive markers of efficacy of cancer therapy. Genetic markers can be used to exclude patients who will not benefit from therapy, exclude patients at high risk of severe toxicity and adjust dosing. Genomic approaches for marker discovery now include genome-wide association studies and tumor DNA sequencing. The challenge is now to select markers for which there is enough evidence to transition them to the clinic. The hurdles include the inherent low frequency of many of these markers, the lengthy validation process through trials, as well as legislative and economic hurdles. Attempts to answer questions about certain markers more quickly have led to an increased popularity of trials with enrichment design, especially in light of the dramatic phase I results seen in recent months. Personalized medicine in oncology is a step closer to reality.
| Authors: | Thomas I. Peng Soh; Wei Peng Yong; Federico Innocenti | |
| Journal: | Clinical Chemistry | |
| Year: | 2011 | |
| DOI: | 10.1515/CCLM.2011.715 | |
| Publication date: | 19-Oct-2011 |
Facts, background information, dossiers
- cancer therapy
- validation
- toxicity
- pharmacogenetics
- oncology
- medicine
- genetic markers
- dosing
- DNA sequencing
More about de Gruyter
- Publications
-
News
Creating invisibility with superconducting materials
A new study published in the De Gruyter journal Nanophotonics by lead authors Huanyang Chen at Xiamen University, China, and Qiaoliang Bao, suggests the use of the material Molybdenum Trioxide (α-MoO3) to replace expensive and difficult to produce metamaterials in the emerging technology of ... more
Is it time to abandon the Nobel Prize?
In a commentary piece authors Clare Fiala and Eleftherios P. Diamandis spawned a debate now further nourished by recent disclosures. Fiala and Diamandis argue that it is time to abandon the Nobel Prize in favor of alternative recognitions which encompass the collaborative nature of modern s ... more
-
Companies
Walter de Gruyter GmbH & Co. KG
The scholarly publishing house of Walter de Gruyter has for decades been synonymous with superior academic and scientific literature. Annually, we publish more than 250 new books, over 60 academic journals, as well as various electronic media. As we cater to the academic world, de Gruyter f ... more
